Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?

Leukemia Research

Volumn 34, Issue 9, 2010, Pages 1119-1120

  Barosi, Giovanni ^a   Magrini, Umberto ^a   Gale, Robert Peter ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anemia; Auto immunity; Myelofibrosis; Myeloproliferative neoplasm

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; CYCLOSPORIN; LENALIDOMIDE; LYMPHOCYTE ANTIBODY; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; THYMOCYTE ANTIBODY;

ANEMIA; AUTOIMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG RESPONSE; ERYTHROPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM ASSOCIATED MYELOFIBROSIS; NOTE; PRIORITY JOURNAL; RISK FACTOR; SYMPTOMATOLOGY; T LYMPHOCYTE;

EID: 77955267782     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.05.010     Document Type: Note

References (5)

1. Bass R.D., Pullarkat V., Feinstein D.I., et al. Pathology of autoimmune myelofibrosis. A report of three cases and a review of literature. Am J Pathol 2001, 116:211-216.
2. Centenara E., Guarnone R., Ippoliti G. Barosi Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report. Haematologica 1998, 83:622-626.
3. Marchetti M., Barosi G., Balestri F., Viarengo G., Gentili S., Barulli S., et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004, 22:424-431.
4. Tefferi A., Cortes J., Verstovsek S., Mesa R.A., Thomas D., Lasho T.L., et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108:1158-1164.
5. Tefferi A., Verstovsek S., Barosi G., Passamonti F., Roboz G.J., Gisslinger H., et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009, 27:4563-4569.